Advertisement

Molecular Medicine

, Volume 14, Issue 7–8, pp 383–394 | Cite as

Proteomic Analysis Permits the Identification of New Biomarkers of Arterial Wall Remodeling in Hypertension

  • Sandrine Delbosc
  • Mounsif Haloui
  • Liliane Louedec
  • Morgan Dupuis
  • Myriam Cubizolles
  • Vladimir N. Podust
  • Eric T. Fung
  • Jean-Baptiste Michel
  • Olivier Meilhac
Research Article

Abstract

Hypertension represents one of the main risk factors for vascular diseases. Genetic susceptibility may influence the rate of its development and the associated vascular remodeling. To explore markers of hypertension-related morbidity, we have used surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry to study changes in proteins released by the aorta of two rat strains with different susceptibilities to hypertension. Fischer and Brown Norway (BN) rats were divided into a control group and a group receiving low-dose N(Q)-nitro-L-arginine methyl ester (L-NAME), a hypertensive drug, interfering with endothelial function. In spite of a significant elevation of blood pressure in both strains in response to L-NAME, BN rats exhibited a lower vascular remodeling in response to hypertension. Proteomic analysis of secreted aortic proteins by SELDI-TOF MS allowed detection of four mass-to-charge ratio (m/z) peaks whose corresponding proteins were identified as ubiquitin, smooth muscle (SM) 22α, thymosin β4, and C-terminal fragment of filamin A, differentially secreted in Fischer rats in response to L-NAME. We have confirmed a strain-dependent difference in susceptibility to L-NAME-induced hypertension between BN and Fischer rats. The greater susceptibility of Fischer rats is associated with aortic wall hypertrophic remodeling, reflected by increased aortic secretion of four identified biomarkers. Similar variations in one of them, SM22α, also were observed in plasma, suggesting that this marker could be used to assess vascular damage induced by hypertension.

Notes

Acknowledgments

Sandrine Delbosc was supported by a grant from MSD-Chibret Laboratory and the French Society of Hypertension. This work was supported by the Leducq Foundation and the manuscript was edited by Mary Osborne-Pellegrin.

References

  1. 1.
    Blot S, Arnal JF, Xu Y, Gray F, Michel JB. (1994) Spinal cord infarcts during long-term inhibition of nitric oxide synthase in rats. Stroke. 25:1666–73.CrossRefGoogle Scholar
  2. 2.
    Henrion D, Dowell FJ, Levy BI, Michel JB. (1996) In vitro alteration of aortic vascular reactivity in hypertension induced by chronic NG-nitro-L-arginine methyl ester. Hypertension. 28:361–6.CrossRefGoogle Scholar
  3. 3.
    Arrell DK, Neverova I, Van Eyk JE. (2001) Cardiovascular proteomics: evolution and potential. Circ. Res. 88:763–73.CrossRefGoogle Scholar
  4. 4.
    Fung ET, Enderwick C. (2002) Protein Chip clinical proteomics: computational challenges and solutions. Biotechniques. Suppl:34–8, 40–1.CrossRefGoogle Scholar
  5. 5.
    Issaq HJ, Veenstra TD, Conrads TP, Felschow D. (2002) The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. 292: 587–92.CrossRefGoogle Scholar
  6. 6.
    Michel JB et al. (1986) Effects of antihypertensive treatment in one-clip, two kidney hypertension in rats. Kidney Int. 29:1011–20.CrossRefGoogle Scholar
  7. 7.
    Dupuis M et al. (2004) Profiling of aortic smooth muscle cell gene expression in response to chronic inhibition of nitric oxide synthase in rats. Circulation. 110:867–73.CrossRefGoogle Scholar
  8. 8.
    Mattson DL, Kunert MP, Roman RJ, Jacob HJ, Cowley AW Jr. (2005) Substitution of chromosome 1 ameliorates L-NAME hypertension and renal disease in the fawn-hooded hypertensive rat. Am. J. Physiol. Renal. Physiol. 288:F1015–22.CrossRefGoogle Scholar
  9. 9.
    Kren V et al. (1997) Genetic isolation of a region of chromosome 8 that exerts major effects on blood pressure and cardiac mass in the spontaneously hypertensive rat. J. Clin. Invest. 99: 577–81.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Poli KA et al. (2000) Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation. 101:264–9.CrossRefGoogle Scholar
  11. 11.
    Corseaux D. (2002) Hemostasis imbalance in experimental hypertension. Mol. Med. 8:169–78.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Arnal JF, el Amrani AI, Chatellier G, Menard J, Michel JB.(1993) Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension. 22:380–7.CrossRefGoogle Scholar
  13. 13.
    Paradis V et al. (2005) Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology. 41:40–7.CrossRefGoogle Scholar
  14. 14.
    Somiari RI, Somiari S, Russell S, Shriver CD. (2005) Proteomics of breast carcinoma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 815: 215–25.CrossRefGoogle Scholar
  15. 15.
    Bernatova I et al. (2002) Wine polyphenols improve cardiovascular remodeling and vascular function in NO-deficient hypertension. Am. J. Physiol. Heart Circ. Physiol. 282:H942–8.CrossRefGoogle Scholar
  16. 16.
    Martens FM et al. (2002) Vessel-specific stimulation of protein synthesis by nitric oxide synthase inhibition: role of extracellular signal-regulated kinases 1/2. Hypertension. 39:16–21.CrossRefGoogle Scholar
  17. 17.
    Rossi MA, Colombini-Netto M. (2001) Chronic inhibition of NO synthesis per se promotes structural intimal remodeling of the rat aorta. J. Hypertens. 19:1567–79.CrossRefGoogle Scholar
  18. 18.
    Duran MC. (2003) Proteomic analysis of human vessels: application to atherosclerotic plaques. Proteomics. 3:973–8.CrossRefGoogle Scholar
  19. 19.
    Martin-Ventura JL et al. (2004) Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 110:2216–9.CrossRefGoogle Scholar
  20. 20.
    Martin-Ventura JL et al. (2006) Biological significance of decreased HSP27 in human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26:1337–43.CrossRefGoogle Scholar
  21. 21.
    Hershko A, Ciechanover A. (1998) The ubiquitin system. Annu. Rev. Biochem. 67:425–79.CrossRefGoogle Scholar
  22. 22.
    Herrmann J, Ciechanover A, Lerman LO, Lerman A. (2004) The ubiquitin-proteasome system in cardiovascular diseases—a hypothesis extended. Cardiovasc. Res. 61:11–21.CrossRefGoogle Scholar
  23. 23.
    Meiners S et al. (2002) Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation. 105:483–9.CrossRefGoogle Scholar
  24. 24.
    Gonzalez W et al. (2000) Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: modulation of proinflammatory signals. Hypertension. 36: 103–9.CrossRefGoogle Scholar
  25. 25.
    Adam PJ, Weissberg PL, Cary NR, Shanahan CM. (1997) Polyubiquitin is a new phenotypic marker of contractile vascular smooth muscle cells. Cardiovasc. Res. 33:416–21.CrossRefGoogle Scholar
  26. 26.
    Morgan KG, Gangopadhyay SS. (2001) Invited review: cross-bridge regulation by thin filament-associated proteins. J. Appl. Physiol. 91:953–62.CrossRefGoogle Scholar
  27. 27.
    Zeidan A et al. (2004) Ablation of SM22alpha decreases contractility and actin contents of mouse vascular smooth muscle. FEBS Lett. 562:141–6.CrossRefGoogle Scholar
  28. 28.
    Zhang JC et al. (2001) Analysis of SM22alphadeficient mice reveals unanticipated insights into smooth muscle cell differentiation and function. Mol. Cell. Biol. 21:1336–44.CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Albinsson S, Nordstrom I, Hellstrand P. (2004) Stretch of the vascular wall induces smooth muscle differentiation by promoting actin polymerization. J. Biol. Chem. 279:34849–55.CrossRefGoogle Scholar
  30. 30.
    Huff T, Muller CS, Otto AM, Netzker R, Hannappel E. (2001) beta-Thymosins, small acidic peptides with multiple functions. Int. J. Biochem. Cell. Biol. 33:205–20.CrossRefGoogle Scholar
  31. 31.
    Boncela J, Smolarczyk K, Wyroba E, Cierniewski CS. (2006) Binding of PAI-1 to endothelial cells stimulated by thymosin beta4 and modulation of their fibrinolytic potential. J. Biol. Chem. 281: 1066–72.CrossRefGoogle Scholar
  32. 32.
    Al-Nedawi KN (2004) Thymosin beta 4 induces the synthesis of plasminogen activator inhibitor 1 in cultured endothelial cells and increases its extracellular expression. Blood. 103:1319–24.CrossRefGoogle Scholar
  33. 33.
    Robertson SP. (2005) Filamin A: phenotypic diversity. Curr. Opin. Genet. Dev. 15:301–7.CrossRefGoogle Scholar
  34. 34.
    Birukov KG et al. (1998) Intraluminal pressure is essential for the maintenance of smooth muscle caldesmon and filamin content in aortic organ culture. Arterioscler. Thromb. Vasc. Biol. 18:922–7.CrossRefGoogle Scholar
  35. 35.
    Usui M et al. (1999) Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension. 34:546–51.CrossRefGoogle Scholar
  36. 36.
    Owens GK, Schwartz SM. (1982) Alterations in vascular smooth muscle mass in the spontaneously hypertensive rat. Role of cellular hypertrophy, hyperploidy, and hyperplasia. Circ. Res. 51:280–9.CrossRefGoogle Scholar

Copyright information

© Feinstein Institute for Medical Research 2008

Authors and Affiliations

  • Sandrine Delbosc
    • 1
  • Mounsif Haloui
    • 1
  • Liliane Louedec
    • 1
  • Morgan Dupuis
    • 2
  • Myriam Cubizolles
    • 3
  • Vladimir N. Podust
    • 3
  • Eric T. Fung
    • 3
  • Jean-Baptiste Michel
    • 1
  • Olivier Meilhac
    • 1
  1. 1.Inserm, U698: HematologyBio-engineering and Cardiovascular Remodeling, CHU X Bichat; University Paris 7 Hôpital Xavier BichatParisFrance
  2. 2.Inserm, U525ParisFrance
  3. 3.Ciphergen Biosystems Inc.FremontUSA

Personalised recommendations